Barclays
INAB icon

Barclays’s IN8bio INAB Stock Holding History

Barclays’s Portfolio INAB Stock Details INAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3
Closed -$28 – 5372
2024
Q3 		$28 Buy
+3
New +$54 ﹤0.01% 5224

Other funds holding INAB

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SIG
Stonegate Investment Group Birmingham, Alabama $4.31B AUM 18.07% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Barclays's INAB Position: Q4 2024 in Review

Barclays sold out of IN8bio (INAB) in Q4 2024, closing a stake of 3 shares — an estimated $28 sold.

Barclays first reported a position in INAB in Q3 2024 and held it in 1 quarter. The position peaked at $28 in Q3 2024. 24 funds tracked by Wall St. Rank hold INAB as of Q4 2024.

  • Barclays reported no remaining IN8bio position as of Q4 2024 after selling out during the quarter.
  • Barclays sold 3 IN8bio shares in Q4 2024, an estimated $28.
  • Barclays first reported a position in IN8bio in Q3 2024 and held it in 1 quarter.
  • Barclays's IN8bio position peaked at $28 in Q3 2024.
  • 24 funds tracked by Wall St. Rank held IN8bio as of Q4 2024.

Based on Barclays's 13F filing for Q4 2024, filed 13 Feb 2025.